Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

Inclusion Criteria: * Informed consent signed. * Male or female 18 years of age or older. * Women of childbearing potential must have a negative pregnancy test at the Enrollment Visit. * Women of childbearing potential must practice medically acceptable methods of birth control during the trial. * Participant must be appropriately communicative and able to differentiate with regard to location and intensity of the pain, and to complete the questionnaires used in this trial. * Participants must have a diagnosis of chronic low back pain; chronic pain defined as pain lasting for at least 3 months prior to enrollment. * Participant's pain must require a strong analgesic (defined as World Health Organization Step III) as judged by the investigator. * Participants who require a washout of co-analgesics at enrolment must have an average pain score (NRS-3) of 5 points or higher. Participants who do not require a washout of co-analgesics at enrollment must have an average pain intensity score (NRS-3) during the last 3 days of 6 points or higher. * The painDETECT diagnostic screening questionnaire must be either "positive" (score of 19 to 38 inclusive) or "unclear" (score of 13 to 18 inclusive). If the participant is being treated with a stable regimen of centrally acting co-analgesics, a "negative" painDETECT score (score 9 points or higher). Inclusion criteria prior to allocation to treatment: * Participants must have an average pain intensity score (NRS-3) during the last 3 days of 6 points or higher. * Participants must score either "positive" (score of 19 to 38 inclusive) or "unclear" (score of 13 to 18 inclusive) on the painDETECT diagnostic screening questionnaire. Exclusion Criteria: * Presence of a clinically significant disease or clinical laboratory values that in the investigator's opinion may affect effectiveness, quality of life, or safety/tolerability assessments. * Presence of active systemic or local infections that may, in the opinion of the investigator, affect the effectiveness, quality of life, or safety/tolerability assessments. * Employees of the investigator or trial site, with direct involvement in this trial or other trials under the direction of the investigator or trial site, as well as family members of employees of the investigator. * Participation in another trial concurrently, or within 4 weeks prior to the Enrollment Visit. * Known to or suspected of not being able to comply with the protocol and/or appropriate use of the Investigati…